webinars.endpts.com Open in urlscan Pro
54.185.102.17  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Endpoints News
 * register now

December 14
12:00 pm - 1:00 pm EST
18:00 - 19:00
LOCAL TIME


POST-SABCS SUMMARY & YEAR IN REVIEW: CTDNA IN DRUG DEVELOPMENT FOR BREAST CANCER

Multiple studies have demonstrated that detection of molecular residual disease
(MRD) is associated with poor prognosis in breast cancer. Ongoing prospective
clinical trials are underway to assess the efficacy of therapeutic interception.

Our expert speakers will discuss the latest data from SABCS 2023 and recent
publications and congresses. This will be followed by a panel discussion on the
future directions and implications for drug development and clinical trial
design in this rapidly evolving space.

Findings presented will span treatment setting, including:

NEOADJUVANT:

 * Early ctDNA dynamics during neoadjuvant chemotherapy predicted clinical
   outcomes in high-risk early-stage HER2-negative breast cancers (Magbanua et
   al, Cancer Cell 2023, George et al., ESMO Breast 2023)
 * How ctDNA monitoring during neoadjuvant therapy could facilitate real-time
   assessment of treatment response, identify patients at high risk of disease
   progression, and inform treatment strategy in the adjuvant setting (George et
   al., SABCS 2023)

POST-OP ADJUVANT & SURVEILLANCE:

 * Early stage TNBC patients who were ctDNA-positive post-op did not clear on
   capecitabine, suggesting a need for novel agents in the adjuvant setting
   (Gupta et al., ESMO Breast 2023)
 * Serial post-operative ctDNA analysis identified patients at very high risk of
   recurrence (Shaw et al., ASCO 2022, Pusztai et al. & Loi et al. & Medford et
   al., SABCS 2023)
 * Ongoing studies are investigating opportunities to identify and treat
   patients with very high risk of recurrence (e.g., DARE and LEADER); serial
   ctDNA testing in the adjuvant setting may be key to enrolling these trials

METASTATIC:

 * Longitudinal ctDNA testing may serve as a useful tool for detection of
   progression and monitoring treatment response in patients treated with
   systemic therapies (Oesterreich et al., SABCS 2023)

SPONSORED BY
SHARE ON

27

days

20

hours

9

minutes
register now
register for the webinar
First name
Last name
Email
Company
Job Title
Country --select--AfghanistanÅland IslandsAlbaniaAlgeriaAmerican
SamoaAndorraAngolaAnguillaAntarcticaAntigua and
BarbudaArgentinaArmeniaArubaAustraliaAustriaAzerbaijanBahamasBahrainBangladeshBarbadosBelarusBelgiumBelizeBeninBermudaBhutanBoliviaBonaire,
Sint Eustatius and SabaBosnia and HerzegovinaBotswanaBouvet IslandBrazilBritish
Indian Ocean TerritoryBrunei DarussalamBulgariaBurkina FasoBurundiCabo
VerdeCambodiaCameroonCanadaCayman IslandsCentral African
RepublicChadChileChinaChristmas IslandCocos (Keeling)
IslandsColombiaComorosCongoCongoCook IslandsCosta RicaCôte
d'IvoireCroatiaCuraçaoCyprusCzechiaDenmarkDjiboutiDominicaDominican
RepublicEcuadorEgyptEl SalvadorEquatorial
GuineaEritreaEstoniaEswatiniEthiopiaFalkland Islands (Malvinas)Faroe
IslandsFijiFinlandFranceFrench GuianaFrench PolynesiaFrench Southern
TerritoriesGabonGambiaGeorgiaGermanyGhanaGibraltarGreeceGreenlandGrenadaGuadeloupeGuamGuatemalaGuernseyGuineaGuinea-BissauGuyanaHaitiHeard
Island and McDonald IslandsHoly SeeHondurasHong Kong
SARHungaryIcelandIndiaIndonesiaIraqIrelandIsle of
ManIsraelItalyJamaicaJapanJerseyJordanKazakhstanKenyaKiribatiKoreaKuwaitKyrgyzstanLao
People's Democratic
RepublicLatviaLebanonLesothoLiberiaLibyaLiechtensteinLithuaniaLuxembourgMacau
SARMadagascarMalawiMalaysiaMaldivesMaliMaltaMarshall
IslandsMartiniqueMauritaniaMauritiusMayotteMexicoMicronesiaMoldovaMonacoMongoliaMontenegroMontserratMoroccoMozambiqueMyanmarNamibiaNauruNepalNetherlandsNew
CaledoniaNew ZealandNicaraguaNigerNigeriaNiueNorfolk IslandNorthern Mariana
IslandsNorth MacedoniaNorwayOmanPakistanPalauPalestinePanamaPapua New
GuineaParaguayPeruPhilippinesPitcairnPolandPortugalPuerto
RicoQatarRéunionRomaniaRussian FederationRwandaSaint BarthélemySaint Helena,
Ascension and Tristan da CunhaSaint Kitts and NevisSaint LuciaSaint Martin
(French part)Saint Pierre and MiquelonSaint Vincent and the GrenadinesSamoaSan
MarinoSao Tome and PrincipeSaudi ArabiaSenegalSerbiaSeychellesSierra
LeoneSingaporeSint Maarten (Dutch part)SlovakiaSloveniaSolomon
IslandsSomaliaSouth AfricaSouth Georgia and the South Sandwich IslandsSouth
SudanSpainSri LankaSurinameSvalbard and Jan
MayenSwedenSwitzerlandTaiwanTajikistanTanzaniaThailandTimor-LesteTogoTokelauTongaTrinidad
and TobagoTunisiaTurkeyTurkmenistanTurks and Caicos
IslandsTuvaluUgandaUkraineUnited Arab EmiratesUnited KingdomUnited States Minor
Outlying IslandsUnited States of AmericaUruguayUzbekistanVanuatuVenezuelaViet
NamVirgin Islands (British)Virgin Islands (U.S.)Wallis and FutunaWestern
SaharaYemenZambiaZimbabweOther
Zip/Postal Code
Questions or comments for the speakers?
register

No cost to register, subject to confirmation

By registering for this event, you accept that you may receive direct
communication from the sponsor(s).

If you are experiencing problems with your registration, please try the Zoom
registration page.


ANGEL RODRIGUEZ

ONCOLOGY MEDICAL DIRECTOR, NATERA

Angel Augusto Rodriguez, MD, is a board-certified medical oncologist who
specializes in breast medical oncology and conducted clinical research with
circulating tumor DNA. Before joining Natera, Dr. Rodriguez practiced at Austin
Cancer Centers and Houston Methodist Cancer Center where he was Director of the
Clinical Trials Office and the Triple Negative Breast Cancer Clinic. While at
Houston Methodist he was the principal investigator of clinical trials and
conducted clinical research with circulating tumor DNA.


ARIELLE MEDFORD

BREAST ONCOLOGIST, MASS GENERAL CANCER CENTER, HARVARD MEDICAL SCHOOL

Arielle Medford, MD, obtained her medical degree from the Johns Hopkins
University School of Medicine. She completed internal medicine residency at the
Massachusetts General Hospital (MGH), where she won several awards including the
Harvard Medical School Resident Teaching Award and the MGH Humanism in Medicine
Award. She subsequently returned to the MGH to serve as Chief Resident. She
completed her medical oncology fellowship at the Dana Farber Cancer
Institute/Mass General Cancer Center, where she also became a clinical
post-doctoral fellow at the Broad Institute of Harvard & MIT. Her research
focuses primarily on the clinical-translational applications of circulating
tumor DNA in early and advanced breast cancer, and how these tools can be used
to lead to more personalized care for individual patients living with breast
cancer. Dr. Medford is a recipient of the Young Investigator Award from the ASCO
Conquer Cancer Foundation.

MODERATOR


JOHN SIMMONS

GLOBAL VP BIOPHARMA, NATERA

John Simmons, PhD, currently leads oncology biopharma partnerships at Natera.
Before joining Natera, John completed his postdoctoral fellowship at the
National Cancer Institute (NCI) and served as Vice President of Translational
Medicine at Personal Genome Diagnostics (PGDx). He received his PhD in Tumor
Biology from Georgetown University.

close


YOUR SEAT IS RESERVED!


POST-SABCS SUMMARY & YEAR IN REVIEW: CTDNA IN DRUG DEVELOPMENT FOR BREAST CANCER

12:00 pm - 1:00 pm EST
18:00 - 19:00 LOCAL TIME

A confirmation email with information on how to join the webinar has been sent
to you.

Before joining, be sure to check system requirements to avoid any connection
issues.

close


REGISTRATION DECLINED


POST-SABCS SUMMARY & YEAR IN REVIEW: CTDNA IN DRUG DEVELOPMENT FOR BREAST CANCER

Apologies, the sponsor for this webinar has opted to block certain domains.

Please feel free to check out our other upcoming webinars at
https://webinars.endpts.com/